Fate therapeutics announces positive interim clinical data from its ft596 and ft516 off-the-shelf, ipsc-derived nk cell programs for b-cell lymphoma

10 of 14 patients in ft596 single-dose escalation cohorts 2 and 3 achieved objective response; 7 patients achieved complete response, including 2 of 3 patients treated with ft596 in combination with rituximab following autologous cd19 car t-cell therapy
FATE Ratings Summary
FATE Quant Ranking